A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by WashU Medicine researchers, the trial is the first to report results for this type of vaccine—known as a neoantigen DNA vaccine—for breast cancer patients.
Neoantigen DNA vaccine shows promise against aggressive breast cancer in clinical trial
